April 11, 2022 – Teleflex Incorporated, a leading global provider of medical technologies, has announced the launch of the UroLift System in Japan for treating benign prostatic hyperplasia (BPH), or enlarged prostate. The UroLift System is now available for purchase, effective immediately. Teleflex previously announced reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo).
BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.1 The UroLift System is a minimally invasive approach to treating BPH that can be performed as a same-day outpatient procedure.2 The UroLift System provides rapid symptom relief for men with BPH and allows a quick recovery time for patients.3 Men can return to their normal routines and can preserve sexual function*4-6 with minimal downtime.2,3 The UroLift System can help improve quality of life.4
Liam Kelly, Chairman, President, and Chief Executive Officer of Teleflex said, “As we execute on our overseas expansion strategy for the UroLift System, Japan represents an important milestone in our progress. The UroLift System offers clinical benefits in the minimally invasive treatment of BPH. Our commercialization in Japan marks another step in our goal to make this novel therapy more broadly available to men outside the United States suffering from BPH. Teleflex remains committed to its goal to make the UroLift System the standard of care in the treatment of BPH globally.”
Nam Lee, Teleflex Managing Director in Japan said, “Launching the UroLift System in Japan and offering new treatment options for patients with BPH is monumental. We are pleased to be able to help more patients with BPH with this proven treatment and look forward to the continued global growth of the UroLift System.”